Joerg Herrmann

Summary

Affiliation: Mayo Clinic
Country: USA

Publications

  1. ncbi request reprint The ubiquitin-proteasome system in cardiovascular diseases-a hypothesis extended
    Joerg Herrmann
    Division of Cardiovascular Diseases, Mayo Clinic, Rochester, MN 55905, USA
    Cardiovasc Res 61:11-21. 2004
  2. pmc Primary proteasome inhibition results in cardiac dysfunction
    Joerg Herrmann
    Division of Cardiovascular Diseases, Mayo Clinic Rochester, 200 First Street, SW, Rochester, MN 55905, USA
    Eur J Heart Fail 15:614-23. 2013
  3. ncbi request reprint The ubiquitin-proteasome system--micro target for macro intervention?
    Joerg Herrmann
    Division of Cardiovascular Diseases Mayo Clinic, Rochester, MN 55905, USA
    Int J Cardiovasc Intervent 7:5-13. 2005
  4. ncbi request reprint Peri-procedural myocardial injury: 2005 update
    Joerg Herrmann
    Department of Internal Medicine, Mayo Clinic Rochester, 200 First Street S W, Rochester, MN 55905, USA
    Eur Heart J 26:2493-519. 2005
  5. ncbi request reprint Chronic proteasome inhibition contributes to coronary atherosclerosis
    Joerg Herrmann
    Division of Cardiovascular Diseases, Mayo Clinic and College of Medicine, Rochester, MN 55905, USA
    Circ Res 101:865-74. 2007
  6. ncbi request reprint Chronic endothelin receptor antagonism prevents coronary vasa vasorum neovascularization in experimental hypercholesterolemia
    Joerg Herrmann
    Division of Cardiovascular Diseases, Mayo Clinic Rochester, Rochester, Minnesota 55905, USA
    J Am Coll Cardiol 39:1555-61. 2002
  7. pmc Expression of lipoprotein-associated phospholipase A(2) in carotid artery plaques predicts long-term cardiac outcome
    Joerg Herrmann
    Division of Cardiovascular Diseases, Department of Internal Medicine, Mayo Clinic College of Medicine, Rochester, MN 55905, USA
    Eur Heart J 30:2930-8. 2009
  8. ncbi request reprint Beneficial effects of antioxidant vitamins on the stenotic kidney
    Alejandro R Chade
    Division of Hypertension, Department of Internal Medicine, Mayo Clinic, Rochester, Minn 55905, USA
    Hypertension 42:605-12. 2003
  9. ncbi request reprint Antioxidant intervention blunts renal injury in experimental renovascular disease
    Alejandro R Chade
    Department of Internal Medicine, Division of Hypertension, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    J Am Soc Nephrol 15:958-66. 2004
  10. ncbi request reprint Experimental hypercholesterolemia differentially affects adventitial vasa vasorum and vessel structure of the left internal thoracic and coronary arteries
    Offer Galili
    Division of Cardiovascular Diseases, Mayo College of Medicine, Rochester, MN 55905, USA
    J Thorac Cardiovasc Surg 129:767-72. 2005

Collaborators

Detail Information

Publications44

  1. ncbi request reprint The ubiquitin-proteasome system in cardiovascular diseases-a hypothesis extended
    Joerg Herrmann
    Division of Cardiovascular Diseases, Mayo Clinic, Rochester, MN 55905, USA
    Cardiovasc Res 61:11-21. 2004
    ..This review summarizes recent findings regarding the ubiquitin-proteasome system in cardiovascular diseases and discusses the potential use of proteasome inhibitors in cardiovascular therapy...
  2. pmc Primary proteasome inhibition results in cardiac dysfunction
    Joerg Herrmann
    Division of Cardiovascular Diseases, Mayo Clinic Rochester, 200 First Street, SW, Rochester, MN 55905, USA
    Eur J Heart Fail 15:614-23. 2013
    ..Utilizing the same model, this study was designed to test the hypothesis that chronic proteasome inhibition (PSI) also leads to structural and functional changes of the heart...
  3. ncbi request reprint The ubiquitin-proteasome system--micro target for macro intervention?
    Joerg Herrmann
    Division of Cardiovascular Diseases Mayo Clinic, Rochester, MN 55905, USA
    Int J Cardiovasc Intervent 7:5-13. 2005
    ....
  4. ncbi request reprint Peri-procedural myocardial injury: 2005 update
    Joerg Herrmann
    Department of Internal Medicine, Mayo Clinic Rochester, 200 First Street S W, Rochester, MN 55905, USA
    Eur Heart J 26:2493-519. 2005
    ..Integrating these new developments into the wealth of clinical information on this topic, this review aims at giving a current perspective on the entity of PMI...
  5. ncbi request reprint Chronic proteasome inhibition contributes to coronary atherosclerosis
    Joerg Herrmann
    Division of Cardiovascular Diseases, Mayo Clinic and College of Medicine, Rochester, MN 55905, USA
    Circ Res 101:865-74. 2007
    ..These findings support the significance of the proteasome and related protein quality control for vascular biology and pathology...
  6. ncbi request reprint Chronic endothelin receptor antagonism prevents coronary vasa vasorum neovascularization in experimental hypercholesterolemia
    Joerg Herrmann
    Division of Cardiovascular Diseases, Mayo Clinic Rochester, Rochester, Minnesota 55905, USA
    J Am Coll Cardiol 39:1555-61. 2002
    ..The purpose of this study was to test the hypothesis that endothelin (ET) receptor antagonism reduces coronary vasa vasorum neovascularization in experimental hypercholesterolemia...
  7. pmc Expression of lipoprotein-associated phospholipase A(2) in carotid artery plaques predicts long-term cardiac outcome
    Joerg Herrmann
    Division of Cardiovascular Diseases, Department of Internal Medicine, Mayo Clinic College of Medicine, Rochester, MN 55905, USA
    Eur Heart J 30:2930-8. 2009
    ..The aim was to test the hypothesis that carotid artery plaque expression of lipoprotein-associated phospholipase A(2) (Lp-PLA(2)) predicts cardiac events...
  8. ncbi request reprint Beneficial effects of antioxidant vitamins on the stenotic kidney
    Alejandro R Chade
    Division of Hypertension, Department of Internal Medicine, Mayo Clinic, Rochester, Minn 55905, USA
    Hypertension 42:605-12. 2003
    ..These observations underscore the involvement of oxidative stress in renal injury in RAS and support a role for antioxidant vitamins in preserving the ischemic kidney...
  9. ncbi request reprint Antioxidant intervention blunts renal injury in experimental renovascular disease
    Alejandro R Chade
    Department of Internal Medicine, Division of Hypertension, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    J Am Soc Nephrol 15:958-66. 2004
    ..This study supports critical pathogenic contribution of increased oxidative stress to renal injury and scarring in RVD and suggests a role for antioxidant strategies in preserving the atherosclerotic and ischemic kidney...
  10. ncbi request reprint Experimental hypercholesterolemia differentially affects adventitial vasa vasorum and vessel structure of the left internal thoracic and coronary arteries
    Offer Galili
    Division of Cardiovascular Diseases, Mayo College of Medicine, Rochester, MN 55905, USA
    J Thorac Cardiovasc Surg 129:767-72. 2005
    ..Hence the current study was designed to characterize and compare the structure of the adventitial vasa vasorum in the left internal thoracic and coronary arteries...
  11. ncbi request reprint Hypertension exacerbates the effect of hypercholesterolemia on the myocardial microvasculature
    Martin Rodriguez-Porcel
    Department of Internal Medicine, Division of Cardiovascular Diseases, Mayo Clinic, Rochester, MN, USA
    Cardiovasc Res 58:213-21. 2003
    ..HC and HT are individually associated with abnormal myocardial vascular function, but whether HT exacerbates the HC-induced myocardial vascular dysfunction remains unclear...
  12. ncbi request reprint Differential effect of experimental hypertension and hypercholesterolemia on adventitial remodeling
    Joerg Herrmann
    Division of Cardiovascular Diseases, Department of Internal Medicine, Mayo Clinic Rochester, MN 55905, USA
    Arterioscler Thromb Vasc Biol 25:447-53. 2005
    ..Intima-media remodeling, as frequently assessed by changes in the external elastic lamina-to-lumen area (EELLA), is well-described in coronary artery disease in contrast to adventitial remodeling, especially in the early disease stage...
  13. ncbi request reprint Enhanced expression of Lp-PLA2 and lysophosphatidylcholine in symptomatic carotid atherosclerotic plaques
    Dallit Mannheim
    Division of Cardiovascular Diseases, Mayo Clinic College of Medicine, Rochester, MN 55905, USA
    Stroke 39:1448-55. 2008
    ..Therefore, this study was performed to test the hypothesis that Lp-PLA(2) expression is higher in symptomatic than in asymptomatic carotid plaques of patients undergoing carotid endarterectomy...
  14. ncbi request reprint Effects of proteasome inhibition on the kidney in experimental hypercholesterolemia
    Alejandro R Chade
    Department of Internal Medicine, Division of Nephrology and Hypertension, Mayo Clinic College of Medicine, 200 First Street SW, Rochester, MN 55905, USA
    J Am Soc Nephrol 16:1005-12. 2005
    ..This study may support a role for the ubiquitin/proteasome system in the kidney in HC and early atherosclerosis...
  15. ncbi request reprint Hypercholesterolemia and hypertension have synergistic deleterious effects on coronary endothelial function
    Martin Rodriguez-Porcel
    Department of Internal Medicine, Division of Cardiovascular Diseases, Mayo Clinic, 200 First St SW, Rochester, Minn 55905, USA
    Arterioscler Thromb Vasc Biol 23:885-91. 2003
    ..However, pathogenic mechanisms are poorly understood. Here we studied the effects of coexisting HC and HT on coronary endothelial function...
  16. pmc Simvastatin preserves diastolic function in experimental hypercholesterolemia independently of its lipid lowering effect
    Dallit Mannheim
    Division of Cardiovascular Diseases, Mayo Clinic, Rochester, MN 55905, USA
    Atherosclerosis 216:283-91. 2011
    ..It has been attributed to myocardial fibrosis and related to cardiovascular risk factor exposure. We hypothesized that simvastatin will improve these dynamics in experimental hypercholesterolemia (HC)...
  17. ncbi request reprint Endothelin-1 receptor blockade prevents renal injury in experimental hypercholesterolemia
    Alejandro R Chade
    Department of Internal Medicine, Division of Hypertension, Mayo Clinic, Rochester, Minnesota, USA
    Kidney Int 64:962-9. 2003
    ..However, the involvement of endothelin (ET) in this disease process is yet unknown...
  18. pmc Repeated episodes of thrombosis as a potential mechanism of plaque progression in cardiac allograft vasculopathy
    Yoshiki Matsuo
    From the Division of Cardiovascular Diseases, Mayo Clinic, Rochester, MN, USA
    Eur Heart J 34:2905-15. 2013
    ..We tested the hypothesis that the multilayer (ML) appearance, an intravascular ultrasound (IVUS) finding suggestive of repetitive thrombosis, is associated with plaque progression in heart transplant (HTx) recipients...
  19. ncbi request reprint Differential distribution of vasa vasorum in different vascular beds in humans
    Heike A Hildebrandt
    Department of Internal Medicine, Division of Cardiovascular Diseases, Mayo Clinic College of Medicine, 200 First Street SW, Rochester, MN 55905, USA
    Atherosclerosis 199:47-54. 2008
    ..This study was designed to describe the distribution of VV density in different vascular beds in humans and to investigate the association between VV density and the known distribution of atherosclerosis in human arteries...
  20. pmc Phase-contrast MRI-based elastography technique detects early hypertensive changes in ex vivo porcine aortic wall
    David A Woodrum
    Radiology Department, Mayo Clinic, Rochester, Minnesota 55905, USA
    J Magn Reson Imaging 29:583-7. 2009
    ..To measure the elastic properties of ex vivo porcine aortas in control and hypertensive groups using a phase contrast magnetic resonance imaging (MRI)-based elastography technique...
  21. pmc On to the road to degradation: atherosclerosis and the proteasome
    Joerg Herrmann
    Department of Internal Medicine, Division of Cardiovascular Diseases, Mayo Clinic Rochester, 200 First Street SW, Rochester, MN 55905, USA
    Cardiovasc Res 85:291-302. 2010
    ..It will conclude with the integration of the available information in a synoptic view of the involvement of the UPS in atherosclerosis...
  22. ncbi request reprint Increased ubiquitin immunoreactivity in unstable atherosclerotic plaques associated with acute coronary syndromes
    Joerg Herrmann
    Division of Cardiovascular Diseases, Mayo Clinic, Rochester, Minnesota 55905, USA
    J Am Coll Cardiol 40:1919-27. 2002
    ..The current study was designed to examine whether ubiquitin expression is higher in unstable than in stable lesions of patients with acute coronary syndrome (ACS)...
  23. ncbi request reprint Body mass index and acute and long-term outcomes after acute myocardial infarction (from the Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction Trial)
    Joerg Herrmann
    Division of Cardiovascular Diseases, Department of Medicine, Mayo Clinic, Rochester, Minnesota
    Am J Cardiol 114:9-16. 2014
    ..In conclusion, as BMI increases, patients have a more extensive adjusted cardiovascular risk profile and disease burden and premature STEMI onset but similar adjusted acute and long-term outcomes. ..
  24. ncbi request reprint Adventitial vasa vasorum heterogeneity among different vascular beds
    Offer Galili
    Division of Cardiovascular Diseases, Mayo Clinic College of Medicine, Rochester, MN 55905, USA
    J Vasc Surg 40:529-35. 2004
    ..Hence, the current study was designed to characterize and compare the structure of the adventitial VV in the coronary and the peripheral circulation...
  25. ncbi request reprint Myocardial bridging
    Jorge R Alegria
    Division of Cardiovascular Diseases, Mayo Clinic, Rochester, MN 55905, USA
    Eur Heart J 26:1159-68. 2005
    ....
  26. ncbi request reprint Myocardial bridging is associated with alteration in coronary vasoreactivity
    Joerg Herrmann
    Division of Cardiovascular Diseases, Mayo Clinic Rochester, 200 First Street S W, Rochester, MN 55905, USA
    Eur Heart J 25:2134-42. 2004
    ..Myocardial bridging is a congenital condition associated with alteration in shear stress, however, its impact upon vasoreactivity remains undetermined...
  27. doi request reprint Potential role of the ubiquitin-proteasome system in atherosclerosis: aspects of a protein quality disease
    Joerg Herrmann
    Department of Internal Medicine, Mayo Clinic, Rochester, Minnesota 55905, USA
    J Am Coll Cardiol 51:2003-10. 2008
    ..This review summarizes these recent findings with a focus on atherosclerosis. In particular, this paper reflects on the viewpoint of atherosclerosis as a protein quality disease...
  28. ncbi request reprint Role of lipoprotein-associated phospholipase A2 in atherosclerosis
    Shahar Lavi
    Division of Cardiovascular Diseases, Mayo Clinic, Rochester, MN 55905, USA
    Curr Atheroscler Rep 10:230-5. 2008
    ..In addition to being a useful marker of a risk factor, several studies suggest that Lp-PLA(2) has a pathophysiologic role in the atherosclerotic disease process. In this article, we review this aspect and its therapeutic implications...
  29. ncbi request reprint Dysregulation of the ubiquitin-proteasome system in human carotid atherosclerosis
    Daniele Versari
    Division of Cardiovascular Diseases, Mayo Clinic Rochester, 200 First St SW, Rochester, MN 55905, USA
    Arterioscler Thromb Vasc Biol 26:2132-9. 2006
    ..The aim of this study was to evaluate the activity of ubiquitin-proteasome system in human carotid artery plaques in relation to oxidative stress and clinical manifestation...
  30. ncbi request reprint Atherosclerosis in the back yard
    Joerg Herrmann
    Department of Internal Medicine, Division of Cardiovascular Diseases, Mayo Clinic, Rochester, Minnesota 55905, USA
    J Am Coll Cardiol 49:2102-4. 2007
    ..In the current focus issue of the Journal, 4 articles and this commentary are devoted to this topic...
  31. ncbi request reprint Ubiquitin and ubiquitin-like proteins in protein regulation
    Joerg Herrmann
    Division of Cardiovascular Diseases, Mayo Clinic Rochester, Rochester, MN 55905, USA
    Circ Res 100:1276-91. 2007
    ..This review provides an overview of this class of molecules and its implication for function, subcellular location, and half-life of proteins...
  32. ncbi request reprint Microcirculatory dysfunction in ST-elevation myocardial infarction: cause, consequence, or both?
    Amir Lerman
    Division of Cardiovascular Disease, Department of Internal Medicine, Mayo Clinic and College of Medicine, 200 First Street SW, Rochester, MN 55902, USA
    Eur Heart J 28:788-97. 2007
    ..In the current work, we aimed at reviewing the role of the coronary microcirculation in the development and outcome of this acute coronary syndrome entity...
  33. pmc Coronary atherosclerosis with vulnerable plaque and complicated lesions in transplant recipients: new insight into cardiac allograft vasculopathy by optical coherence tomography
    Andrew Cassar
    Division of Cardiovascular Diseases, Department of Internal Medicine, Mayo College of Medicine, 200 First Street SW, Rochester, MN 55905, USA
    Eur Heart J 34:2610-7. 2013
    ..Our aim was to characterize CAV in vivo using the high spatial resolution of intracoronary optical coherence tomography (OCT)...
  34. pmc Humanin, a cytoprotective peptide, is expressed in carotid atherosclerotic [corrected] plaques in humans
    David G Zacharias
    Division of Cardiovascular Diseases, Department of Nephrology and Hypertension, Mayo Clinic College of Medicine, Rochester, Minnesota, United States of America
    PLoS ONE 7:e31065. 2012
    ..Humanin (HN) is a newly emerging endogenously expressed cytoprotective peptide. Our goal was to determine the presence and localization of HN in carotid atherosclerotic plaques...
  35. ncbi request reprint Angiogenesis in atherogenesis
    Joerg Herrmann
    Division of Cardiovascular Diseases, Mayo Clinic, 200 First St SW, Rochester, MN 55905, USA
    Arterioscler Thromb Vasc Biol 26:1948-57. 2006
    ..This article gives an updated overview on this topic and briefly reflects on the similarities with neovessel formation in carcinogenesis...
  36. ncbi request reprint Simvastatin preserves the structure of coronary adventitial vasa vasorum in experimental hypercholesterolemia independent of lipid lowering
    Stephanie H Wilson
    Divisions of Cardiovascular Diseases, Mayo Clinic, Rochester, MN 55905, USA
    Circulation 105:415-8. 2002
    ..We aimed to determine the effect of simvastatin on coronary VV neovascularization, in the absence of cholesterol lowering...
  37. doi request reprint High sensitivity C-reactive protein and outcomes following percutaneous coronary intervention in contemporary practice
    Joerg Herrmann
    Division of Cardiovascular Diseases, Department of Medicine, Mayo Clinic, Rochester, MN, USA
    Circ Cardiovasc Interv 5:783-90. 2012
    ..Whether hsCRP is a useful biomarker for risk stratification in contemporary percutaneous coronary intervention remains unknown...
  38. pmc Coronary microvascular dysfunction in the clinical setting: from mystery to reality
    Joerg Herrmann
    Division of Cardiovascular Disease, Department of Internal Medicine, Mayo Clinic, Rochester, NY, USA
    Eur Heart J 33:2771-2782b. 2012
    ..As such, this review aims to remove at least some of the mystery surrounding the notion of coronary microvascular dysfunction and to show why it represents a true clinical entity...
  39. ncbi request reprint C-reactive protein relaxes human vessels in vitro
    Leonid Sternik
    Division of Cardiovascular Surgery, Mayo Clinic and The Mayo Foundation, Rochester, Minn 55905, USA
    Arterioscler Thromb Vasc Biol 22:1865-8. 2002
    ..Evidence suggests direct biological activities of CRP within the vascular wall. The study was designed to examine the vasoreactive effects of CRP...
  40. ncbi request reprint The endothelium - the cardiovascular health barometer
    Joerg Herrmann
    Division of Cardiovascular Diseases, Mayo Clinic, Rochester, MN 55905, USA
    Herz 33:343-53. 2008
    ..From past conceptual ideas to current practical applications to the road ahead, the endothelium is to be viewed as the cardiovascular health barometer...
  41. ncbi request reprint Preprocedural statin medication reduces the extent of periprocedural non-Q-wave myocardial infarction
    Joerg Herrmann
    Department of Cardiology, University Clinic Essen, Essen, Germany
    Circulation 106:2180-3. 2002
    ..Thus, we tested the hypothesis that preprocedural statin therapy is associated with a reduction in the extent of stenting-related myocardial injury...
  42. ncbi request reprint New kits on the blot--can we microarray the future of atherosclerosis?
    Joerg Herrmann
    Cardiovasc Res 60:220-2. 2003
  43. ncbi request reprint c-Myc oncoprotein: cell cycle-related events and new therapeutic challenges in cancer and cardiovascular diseases
    Filomena de Nigris
    Department of Pharmacological Sciences, University of Salerno, Salerno, Italy
    Cell Cycle 2:325-8. 2003
    ..In general, the increased biologic understanding of the participation of cell cycle events and targeting these events may enable to attenuate or prevent some of the complications of vascular and neoplastic diseases...
  44. ncbi request reprint Endothelial function under pressure
    Amir Lerman
    J Am Coll Cardiol 41:1759-60. 2003